FDA Regulation of Dietary Supplements and Requirements Regarding Adverse Event Reporting

被引:36
|
作者
Frankos, V. H. [1 ]
Street, D. A. [2 ]
O'Neill, R. K. [3 ]
机构
[1] US FDA, Div Dietary Supplement Programs, College Pk, MD USA
[2] US FDA, Emergency Response & Surveillance Branch, College Pk, MD USA
[3] US FDA, Div Publ Hlth & Biostat, College Pk, MD USA
关键词
D O I
10.1038/clpt.2009.263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In 1994, the Dietary Supplement Health and Education Act (DSHEA) amended the Federal Food, Drug, and Cosmetic Act (FDC Act) to set up a distinct regulatory framework for what we now call dietary supplements. The DSHEA was passed with the intent of striking a balance between providing consumers access to safe dietary supplements to help maintain or improve their health and giving the US Food and Drug Administration (FDA) authority to regulate and take action against manufacturers of supplements or supplement ingredients that present safety problems, are presented with false or misleading claims, or are adulterated or misbranded. This article will present FDA's recent experience in collecting and evaluating dietary supplement adverse event data for the purpose of assuring the public that the dietary supplements they purchase are safe.
引用
下载
收藏
页码:239 / 244
页数:6
相关论文
共 50 条
  • [41] Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
    Fukuda, Akiho
    Tahara, Kohei
    Hane, Yuuki
    Matsui, Toshinobu
    Sasaoka, Sayaka
    Hatahira, Haruna
    Motooka, Yumi
    Hasegawa, Shiori
    Naganuma, Misa
    Abe, Junko
    Nakao, Satoshi
    Takeuchi, Hirofumi
    Nakamura, Mitsuhiro
    PLOS ONE, 2017, 12 (09):
  • [42] Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
    Caldito, Natalia Gonzalez
    Shirani, Afsaneh
    Salter, Amber
    Stuve, Olaf
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (07) : 1066 - 1076
  • [43] Adverse event profile differences between rituximab and ocrelizumab: findings from the fda adverse event reporting database
    Caldito, N. Gonzalez
    Shirani, A.
    Salter, A.
    Stuve, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 257 - 257
  • [44] Dietary supplements and FDA reporting compliance: The adaption of an existing SAE reporting system to new corporate needs
    Abe, K.
    Aizawa, K.
    Fujimaki, K.
    Ostrander, J.
    PLANTA MEDICA, 2014, 80 (10) : 851 - 852
  • [45] Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS)
    Vermeer, N. S.
    Straus, S. M.
    Teeuwisse, A. K. Mantel
    Egberts, T. C.
    Leufkens, H. G.
    De Bruin, M. L.
    DRUG SAFETY, 2011, 34 (10) : 1002 - 1002
  • [46] Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database
    Shah, Divya
    Stone, Cosby
    Rukasin, Christine
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB77 - AB77
  • [47] Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013
    Timbo, Babgaleh B.
    Chirtel, Stuart J.
    Ihrie, John
    Oladipo, Taiye
    Velez-Suarez, Loy
    Brewer, Vickery
    Mozersky, Robert
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (05) : 431 - 438
  • [48] Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
    Li, Ying
    Yepes, Antonio Jimeno
    Xiao, Cao
    DRUG SAFETY, 2020, 43 (09) : 893 - 903
  • [49] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [50] Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System
    Swisher, Austin R.
    Kshirsagar, Rijul S.
    Adappa, Nithin D.
    Liang, Jonathan
    LARYNGOSCOPE, 2022, 132 (12): : 2307 - 2313